Information Provided By: 
Fly News Breaks for October 10, 2019
PRNB
Oct 10, 2019 | 11:07 EDT
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating and $55 price target on Principia Biopharma after the company announced positive interim data from the open label Part B of its PRN1008 Phase 2 trial in pemphigus vulgaris, or PV, which included the selection of an optimized dosing. In a note to investors titled 'Consistency Is the Message of the Day for PV Efficacy,' the analyst said the Phase 2 results helped to boost his confidence in the ongoing Pegasus Phase 3 trial of PRN1008 in PV.
News For PRNB From the Last 2 Days
There are no results for your query PRNB
